CHICAGO – Cardio Diagnostics Holdings, Inc (the “Company”) (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that it has entered into a securities purchase agreement (“Securities...
CHICAGO – Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced Dr. Damon Broyles, MD, the VP of Clinical Innovation at Mercy Technology Services (MTS), the technical...
CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research...
PrecisionCHD™ is the First Integrated Epigenetic-Genetic-Based Blood Test for the Early Detection of Coronary Heart Disease CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine...
PrecisionCHD is the only precision cardiovascular medicine test at the intersection of epigenetics, genetics, and artificial intelligence for the early detection of coronary heart disease. CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial...
Leading Medical Practice in Idaho Will be the First Functional Medicine Clinic to Offer the Epi+Gen CHD Precision Cardiovascular Test CHICAGO – Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Healing...
